LigaChem Biosciences
리가켐바이오 · 141080
Health Care Biotechnology · KOSDAQ
Market cap US$4B (₩5.5T)
Overview
LigaChem Biosciences develops cancer-fighting drugs that work by attaching a toxic payload directly to an antibody, which then seeks out and targets tumor cells, a class of medicines known as antibody-drug conjugates, or ADCs.
The company also researches synthetic small-molecule drugs, including treatments for antibiotic-resistant bacterial infections, and supplies medical consumables and devices to hospitals. Listed on KOSDAQ, Korea's tech-focused stock exchange, it operates primarily as a drug-discovery and technology-licensing business, generating revenue by out-licensing its proprietary ADC platform, called ConjuALL, to global pharmaceutical companies.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$24.7M
- FY2024US$91.2M
- FY2025US$102.6M
Operating profit
- FY2023−US$58.6M
- FY2024−US$15.2M
- FY2025−US$77.2M
Net income
- FY2023−US$53.4M
- FY2024US$5.7M
- FY2025−US$66.3M
Key ratios (FY2025)
Why it matters
The company has licensed its ConjuALL ADC platform technology to multiple global pharmaceutical companies and has received the Best ADC Platform Technology award at the World ADC Awards on several occasions.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?